H.C. Wainwright analyst Swayampakula Ramakanth has maintained their bullish stance on DNTH stock, giving a Buy rating today.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors related to the promising potential of Dianthus Therapeutics’ DNTH103. The analyst is optimistic about the upcoming topline data from the Phase 2 MaGic study, which is expected to demonstrate best-in-class potential for treating generalized Myasthenia Gravis (gMG). The study aims to evaluate DNTH103, a C1s inhibitor, and is anticipated to show a favorable safety profile and significant efficacy, positioning it competitively against existing treatments.
Additionally, the ongoing Phase 3 CAPTIVATE study in chronic inflammatory demyelinating polyneuropathy (CIDP) and the Phase 2 MoMeNtum study in Multifocal Motor Neuropathy (MMN) further support the Buy rating. The CAPTIVATE study is considered de-risked due to positive Phase 2 data, and interim results are expected in the second half of 2026. The MoMeNtum study, designed similarly to MaGic, is also progressing well, with results anticipated in the same timeframe. These developments, along with DNTH103’s convenient dosing regimen and potential to become a standard frontline treatment, underpin the positive outlook for Dianthus Therapeutics.
Questions or Comments about the article? Write to editor@tipranks.com